Correspondence 0001104659-24-127650 from Samsara BioCapital, L.P. (CIK 0001699737)
Samsara BioCapital, L.P. (CIK 0001699737)
Date: Dec. 11, 2024 · CIK: 0001699737 · Accession: 0001104659-24-127650
AI Filing Summary & Sentiment
Letter
Re: Samsara BioCapital GP, LLC
December 11, 2024
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-4628
Attention: Division of Corporation Finance
Office of Mergers & Acquisitions
Alumis Inc.
Schedule 13D by Samsara BioCapital, L.P.; Samsara BioCapital GP, LLC; and
Srinivas Akkaraju
Filed August 27, 2024
File No. 005-94550
Ladies and Gentlemen:
On behalf of Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju (collectively, “Samsara” or the “Reporting Persons”), we are responding to the comment contained in the letter from the staff (the “Staff”) of the United States Securities and Exchange Commission dated December 3, 2024 relating to the above-referenced filing. The Reporting Persons’ response is set forth below the Staff’s comment.
Schedule 13D Filed August 27, 2024
General
1. We note that the event reported as requiring the filing of the Schedule 13D was July 1, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the July 1, 2024 event date, the Schedule 13D submitted on August 27, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date of the acquisition.
Response:
We respectfully advise the Staff that the late filing resulted from an administrative oversight and that Samsara filed the Schedule 13D promptly following its recognition that the filing had been triggered by Samsara’s purchase in Alumis Inc.’s initial public offering. We also advise the Staff that, subsequent to the transaction, Samsara has reviewed, with outside counsel, the rules and regulations under Section 13 of the Securities Exchange Act and has reassigned and clarified certain internal roles and responsibilities to ensure that public securities transactions are carefully tracked and that future Section 13 filing requirements are identified in a timely manner.
* * * *
If you have any questions or require any additional information with respect to the foregoing, please contact the undersigned at (703) 456-8034.
Sincerely,
/s/ Darren DeStefano
Show Raw Text
CORRESP
1
filename1.htm
December 11, 2024
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-4628
Attention:
Division of Corporation Finance
Office of Mergers & Acquisitions
Re: Samsara BioCapital GP, LLC
Alumis Inc.
Schedule 13D by Samsara BioCapital, L.P.; Samsara BioCapital
GP, LLC; and
Srinivas Akkaraju
Filed August 27, 2024
File No. 005-94550
Ladies and Gentlemen:
On behalf of Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and
Srinivas Akkaraju (collectively, “Samsara” or the “Reporting Persons”), we are responding
to the comment contained in the letter from the staff (the “Staff”) of the United States Securities and Exchange
Commission dated December 3, 2024 relating to the above-referenced filing. The Reporting Persons’ response is set forth below
the Staff’s comment.
Schedule 13D Filed August 27, 2024
General
1. We note that the event reported as requiring the filing of the Schedule 13D was July 1, 2024. Rule 13d-1(a) of Regulation
13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of
a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the July 1, 2024 event date, the Schedule
13D submitted on August 27, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five
business days after the date of the acquisition.
Response:
We respectfully advise the Staff that the late filing
resulted from an administrative oversight and that Samsara filed the Schedule 13D promptly following its recognition that the filing had
been triggered by Samsara’s purchase in Alumis Inc.’s initial public offering. We also advise the Staff that, subsequent to
the transaction, Samsara has reviewed, with outside counsel, the rules and regulations under Section 13 of the Securities Exchange
Act and has reassigned and clarified certain internal roles and responsibilities to ensure that public securities transactions are carefully
tracked and that future Section 13 filing requirements are identified in a timely manner.
* * * *
If you have any questions or require any additional
information with respect to the foregoing, please contact the undersigned at (703) 456-8034.
Sincerely,
/s/ Darren DeStefano